Sunday, July 20, 2025 1:10:07 PM
After the agreements between NWBio and Private Clinics are completed and signed throughout the UK, then I believe these NWBIo and Private Clinics agreements will be emulated throughout the EU to cover all 26 EU countries, including Germany, France, Italy, Spain, etc.
Then, I believe NWBio will pursue the same strategy with Private Clinics throughout the U.S. and Canada.
Again, the main purposes of these Private Clinics agreements are:
(1) Create dedicated leukapheresis units that are available to NWBio patients at all time.
(2) To potentially use these Private Clinics sites as future clinical trial sites for DCVax-L, DCVax-Direct, and any other future Roswell Park IP clinical trials. The contracted Private Clinics will be able to administer the DCVax vaccine doses, to clinical trial participants, at their locations.
(3) To be able to treat future Compassionate Use patients, with any type of solid tumor cancer. The contracted Private Clinics will be able to administer the DCVax vaccine doses, to Compassionate Use patients, at their locations.
Then, I believe NWBio will pursue the same strategy with Private Clinics throughout the U.S. and Canada.
Again, the main purposes of these Private Clinics agreements are:
(1) Create dedicated leukapheresis units that are available to NWBio patients at all time.
(2) To potentially use these Private Clinics sites as future clinical trial sites for DCVax-L, DCVax-Direct, and any other future Roswell Park IP clinical trials. The contracted Private Clinics will be able to administer the DCVax vaccine doses, to clinical trial participants, at their locations.
(3) To be able to treat future Compassionate Use patients, with any type of solid tumor cancer. The contracted Private Clinics will be able to administer the DCVax vaccine doses, to Compassionate Use patients, at their locations.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM

